logo
Plus   Neg
Share
Email

G-III Apparel Cuts FY20 Earnings Outlook - Quick Facts

While reporting financial results for the second quarter on Thursday, G-III Apparel Group, Ltd. (GIII) lowered its earnings guidance for the full-year 2020, while raising annual sales outlook.

For fiscal 2020, the company now projects earnings in the range $3.10 and $3.20 per share and adjusted earnings in the range of $3.15 to $3.25 per share on net sales of about $3.30 billion.

Previously, the company expected earnings in the range $3.19 and $3.29 per share and adjusted earnings in the range of $3.25 to $3.35 per share on net sales of about $3.28 billion.

For the third quarter, the company anticipates earnings in a range $1.85 to $1.95 per share and adjusted earnings in a range of $1.87 to $1.97 per share on net sales of about $1.17 billion.

The company said the guidance incorporates the expected impact of the additional tariffs implemented effective September 1, 2019 and expected to be implemented later this year. The prior guidance issued last quarter incorporated the effect of tariffs in effect at that time.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
India-based Lupin Pharmaceuticals Inc. announced a recall of all batches of type 2 diabetes medication Metformin Hydrochloride Extended-Release Tablets, citing detection of N-Nitrosodimethylamine or NDMA, a probable human carcinogen. The move comes after many other drug companies called back Metformin tablets after the U.S. Food and Drug Administration or FDA recommended over NDMA concerns. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the current state of the COVID-19 pandemic in the U.S. is "really not good." The U.S. is the country worst-affected by the coronavirus and has recently seen a surge in coronavirus infections as lockdown restrictions are eased. Granules Pharmaceuticals, Inc. recalled twelve (12) lots of type 2 diabetes medication Metformin hydrochloride Extended-Release, in the form of oral film-coated tablets, for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
RELATED NEWS
Follow RTT